Jonathan Zalevsky Sells 10,300 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $1.01, for a total transaction of $10,403.00. Following the completion of the transaction, the insider now directly owns 316,604 shares of the company’s stock, valued at approximately $319,770.04. This represents a 3.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10.

Nektar Therapeutics Stock Down 2.6 %

Shares of NASDAQ NKTR opened at $0.93 on Friday. Nektar Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.93. The firm’s 50-day simple moving average is $0.92 and its 200 day simple moving average is $1.12. The stock has a market cap of $171.95 million, a P/E ratio of -1.11 and a beta of 0.58.

Institutional Investors Weigh In On Nektar Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its position in Nektar Therapeutics by 801.4% in the fourth quarter. Mackenzie Financial Corp now owns 469,769 shares of the biopharmaceutical company’s stock worth $437,000 after acquiring an additional 417,651 shares in the last quarter. US Asset Management LLC bought a new stake in Nektar Therapeutics in the fourth quarter worth about $31,000. Woodline Partners LP raised its position in Nektar Therapeutics by 187.3% in the fourth quarter. Woodline Partners LP now owns 4,974,512 shares of the biopharmaceutical company’s stock worth $4,626,000 after acquiring an additional 3,242,841 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Nektar Therapeutics in the fourth quarter worth about $130,000. Finally, Two Sigma Investments LP raised its position in Nektar Therapeutics by 12.8% in the fourth quarter. Two Sigma Investments LP now owns 1,537,355 shares of the biopharmaceutical company’s stock worth $1,430,000 after acquiring an additional 174,185 shares in the last quarter. 75.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. B. Riley assumed coverage on shares of Nektar Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $4.00 price target for the company. Piper Sandler assumed coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.